Hypertension (High Blood Pressure) News and Research

RSS

Hypertension (or high blood pressure) is a condition where the pressure of the blood flowing through the arteries of the body is higher than it should be. Much like the pressure of the air in a tire, if the pressure of the blood is too high it can damage the arteries and organs of the body. Just like the tire, if the pressure suddenly becomes very high, catastrophic events can happen. Similarly, if the pressure remains somewhat elevated for a long enough period of time, premature wear and failure can occur.

Hypertension has its worst effects on the heart, kidneys, eyes, and brain. High blood pressure is a risk factor for heart attack, stroke, kidney failure, hemorrhages of the retina of the eye, and generalized atherosclerosis (hardening of the arteries all over the body).

Resverlogix receives FDA approval to start clinical trial for RVX-208

Resverlogix Corp. has announced that it has received approval by the US Food and Drug Administration (FDA) to initiate a Phase 1a clinical trial of oral RVX-208 in the USA. RVX-208 is a novel first-in-class small molecule that increases the production of ApoA-I and HDL.

10 Dec 2007

New minimally invasive method to repair tears in the aorta

Tears in the aorta which affect thousands of people each year coast to coast, may soon be treated with a much less invasive technique that could dramatically improve patients' chances of survival.

10 Dec 2007

Safe and effective therapy discovered for patients with protein-losing enteropathy

Researchers at the Burnham Institute for Medical Research (Burnham Institute) have developed the first model to study intestinal protein leakage in mice, allowing the team to control and replicate both genetic deficiencies and environmental damages in an in vivo setting.

10 Dec 2007

Adrenalectomy shown to benefit those with mild Cushing syndrome

Researchers at UT Southwestern Medical Center have found that patients with a mild form of Cushing syndrome, a metabolic disorder caused by adrenal tumors, demonstrate substantial clinical improvement after adrenalectomy.

10 Dec 2007

Research findings link weight gain and diabetes to a variety of cancers

During this holiday season with its tempting bounty of edible delights, new research calls attention to the role of the expanding American waistline in health and medicine.

10 Dec 2007

Tuberculosis found in 500,000-year-old human

Although most scientists believe tuberculosis emerged only several thousand years ago, new research from The University of Texas at Austin reveals the most ancient evidence of the disease has been found in a 500,000-year-old human fossil from Turkey.

10 Dec 2007

Caraco Pharmaceutical Labs announces FDA approval to market generic Norvasc

Caraco Pharmaceutical Laboratories has announced that the US Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Amlodipine Besylate Tablets, 2.5 mg, 5 mg, and 10 mg (Amlodipine).

5 Dec 2007

Lead exposure hinders brain's ability to recover from injury

Exposure to lead can hinder the brain's ability to recover from injury, a recent study in laboratory animals shows.

4 Dec 2007

Approval of Diovan (valsartan) in U.S. for hypertension in children and adolescents

Diovan (valsartan), an angiotensin receptor blocker or ARB, has been approved following a priority review by the U.S. Food and Drug Administration (FDA) for the treatment of high blood pressure in children and adolescents ages six to 16.

4 Dec 2007

Not enough sleep raises the risk for diabetes

The most common factors believed to contribute to diabetes are a decreased amount of physical activity and access to highly palatable processed foods.

3 Dec 2007

FDA under pressure to do something about salt in foods

The Food and Drug Administration in the United States is coming under increasing pressure to enforce tougher regulations on the amount of sodium in food.

3 Dec 2007

FDA issues approvable letter for Nebivolol for the treatment of hypertension

Forest Laboratories, Inc. and Mylan Inc. announced that Mylan has received an approvable letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for nebivolol (proposed brand name Bystolic), a novel beta blocker under review for the treatment of hypertension.

2 Dec 2007

Childhood sleep-disordered breathing disproportionately affects obese and African-Americans

As the obesity epidemic grows in the U.S., doctors are discovering more and more far reaching health concerns for overweight children.

2 Dec 2007

Hypertension may heighten effects of Alzheimer's disease

Having hypertension, or high blood pressure, reduces blood flow in the brains of adults with Alzheimer's disease, according to a new study presented at the annual meeting of the Radiological Society of North America (RSNA).

29 Nov 2007

What's needed to protect the heart during such operations?

It's too bad that ticker trouble doesn't guarantee good health elsewhere in the body. Most people with heart disease have other ailments, including some that require surgery.

27 Nov 2007

Ikaria's INOmax approved in Australia

Ikaria Holdings, Inc., through its subsidiary INO Therapeutics LLC, announced today that it has received approval from Australia's regulatory body, the Therapeutic Goods Administration (TGA), for INOmax (nitric oxide) for inhalation.

27 Nov 2007

Communication key to tackling cardiovascular disease

Despite the increasing evidence that managing high cholesterol reduces cardiovascular events, many people do not achieve recommended lipid levels.

27 Nov 2007

New drug called nitrosyl-cobinamide could potentially be used to treat hypertension and heart disease

Investigators at the University of California, San Diego School of Medicine have developed a new drug called nitrosyl-cobinamide.

27 Nov 2007

GlaxoSmithKline to acquire Reliant Pharmaceuticals

GlaxoSmithKline and Reliant Pharmaceuticals Inc. have announced that they had reached an agreement under which Reliant will be acquired by GSK for $1.65 billion (800 million pounds Sterling) in cash.

21 Nov 2007

Avastin (bevacizumab) shows promise in phase II study of glioblastoma multiforme

Genentech, Inc. has announced that both study arms of a randomized, multi-center Phase II clinical study of Avastin (bevacizumab) administered alone or in combination with irinotecan chemotherapy demonstrated encouraging six-month progression-free survival (PFS) and objective response rate in patients with relapsed glioblastoma multiforme (GBM), the most common and aggressive type of brain cancer.

19 Nov 2007